Table 2.
Comparison of the embryonic cerebellar compartments with previous reports by marker and age
| Referencea | Marker | Age | Vermis | Pars intermedia | Hemisphere | Paraflocculus | Flocculus | Nodulus | ||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | β-gal1NM13, PLCβ4, EphA4, Pcdh10 | E17.5 | vt1 | vt4 | vt2 | vt3 | va2 | vp1 | vp2 | vp3 | vp4 | vc2 | vc1 | vt5 | va1 | va3 | va4 | ic2 | ic1 | ip2 | ia1 | ia2 | ia4 | ip1 | ip3 | it2 | ic4 | ic5 | ia3 | ic3 | it3 | ia5 | hc1 | hc2 | hp1 | ha1 | hp3 | ha3 | hp2 | ha2 | ha4 | hp4 | ha6 | ha5 | pf1 | pf2 | fl2 | fl1 | fl3 | fl4 | fl5 | no1 | no2 | no3 | no4 | no5 |
| 2 | Birthdate | E18.5 | 1 | – | 2 | 2? | 4 | 2 | 2 | 4 | – | – | 2 | 3 | – | – | – | 5 | – | – | 5 | 5 | 6? | – | – | 6 | 5 | 6? | 5 | 5 | 7 | 7 | – | – | 8 | 8 | 8 | 8 | 8 | 8 | – | 8 | – | – | 8 | – | – | – | – | – | – | – | – | – | – | – |
| 3 | En1 | E17.5 | B1 | – | B1 | B1 | – | – | – | – | – | – | – | B2 | – | – | – | – | – | – | – | – | – | – | – | B3 | – | B3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 4 | En2 | E17.5 | B1 | – | B2 | B2 | – | – | – | – | – | – | – | – | – | – | B3 | – | – | – | B3 | B3 | – | – | – | B4 | – | B4? | B3 | B3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 5 | Pcp2-CreER-IRES-hAP | E18.5 | – | – | 1 | – | – | 1 | 1? | – | – | – | 1 | 2 | – | – | – | 3 | 3? | – | – | – | – | – | – | 4–5 | – | 4 | – | 3/4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 6 | Pcp2-lacZb | E17 | – | – | 1 | 2? | – | 1 | 2? | 3 | – | – | 1/2 | – | – | – | – | 4–5 | 4–5? | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 7? | 7? | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 7 | Neurogranin | E17 | – | – | 1 | 2 | – | – | – | – | – | – | – | 3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 4? | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 8 | PKGc | E19 (rat)d | I | – | I | I | – | – | – | – | – | – | – | – | II | – | – | III | III | – | – | – | – | – | – | IV | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | I | – | – | – |
| 9 | Tritium-labelinge | E21 (rat) | – | C1? | – | C4? | – | – | C2? | – | – | – | – | C5? | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | C3 | – | – | – |
a Reference key is as follows: 1, The present study; 2, Hashimoto and Mikoshiba (2003); 3, 4, Wilson et al. (2011); 5, Sillitoe et al. (2009); 6, Fig. 2 of Oberdick et al. (1993); 7, Larouche et al. (2006); 8, Fig. 4B of Wassef et al. (1984); 9, Fig. 12-1D of Altman and Bayer (1997). Since the previous studies were based on a small number of sections and/or whole-mount preparations, these studies seems to be inadequate for identifying the complete set of compartments that were identified in the present study. Correspondence was inferred based on the shape and localization of the clusters and the reported expression patterns of marker molecules. In some cases, when the nomenclature was not consistent through the study, we focused on a particular figure of the study.
b 0.5 kb promoter line, L7BG3-L12.
c PKG is cGK (cyclic 3′,5′-guanosine monophosphate-dependent protein kinase).
d Studies were performed in the mouse unless “rat” is added.
e The section was counterstained with cresyl violet and toluidine blue.